Innovative Assay Platform Aushon BioSystems offers a comprehensive multiplex immunoassay platform with over 300 biomarkers, providing reliable and high-performance protein biomarker data that can support pharmaceutical, biotech, and academic clients seeking efficient research solutions.

Growth Through Acquisition Following its acquisition by Quanterix in 2018, there is potential for expanded product integration and cross-selling opportunities, leveraging Quanterix’s high-sensitivity immunoassay technologies to enhance Aushon’s offerings.

Recent Product Launches The launch of ultra-sensitive multiplex assays in 2016 and 2017 highlights Aushon’s focus on cutting-edge sensitivity and multiplexing capabilities, appealing to customers in need of precise and high-throughput biomarker detection.

Funding & Market Position With nearly $6.8 million in recent funding and annual revenues between one to ten million dollars, Aushon is a growth-oriented company actively investing in innovation, making it a promising partner for collaborations and supply agreements.

Targeted Customer Base Aushon’s clientele includes leading pharmaceutical, biotechnology, and academic institutions, providing opportunities to offer tailored solutions that address the evolving needs of high-growth research sectors within the life sciences industry.